Retinal vein occlusion: Therapy of retinal vein occlusion;Retinaler Venenverschluss: Therapie des retinalen Venenverschlusses

Ophthalmologe

Volumn 112, Issue 8, 2015, Pages 695-706

  Feltgen, N ^a   Pielen, A ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Universitäts Augenklinik Hannover   (Germany)

Author keywords

Intravitreal injection; Macular edema; Ophthalmology; Retina; Vascular disease

Indexed keywords

ANGIOGENESIS INHIBITOR; CORTICOSTEROID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; EVIDENCE BASED MEDICINE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; MULTIMODALITY CANCER THERAPY; PROCEDURES; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; INTRAVITREAL INJECTIONS; LIGHT COAGULATION; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939257642     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-015-0115-6     Document Type: Article

References (37)

1. Heinen A, Brunner R, Hossmann V, Konen W, Roll K, Wawer T (1984) Veränderungen hämorheologischer und gerinnungsphysiologischer Parameter bei unterschiedlicher Therapie von retinalen Durchblutungsstörungen – eine randomisierte Doppelblindstudie. Fortschr Ophthalmol 81:444–448
2. Chen HC, Wiek J, Gupta A, Luckie A, Kohner EM (1998) Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 82:162–167
3. Roth S (1992) The effects of isovolumic hemodilution on ocular blood flow. Exp Eye Res 55(1):59–63
4. Wolf S, Arend O, Bertram B, Remky A, Schulte K, Wald KJ et al (1994) Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol 232(1):33–39
5. Remky A, Wolf S, Hamid M, Bertram B, Schulte K, Arend O et al (1994) Effekt der Hämodilution auf die retinale Hämodynamik bei Patienten mit retinalem Venenastverschluss. Ophthalmologe 91:288–292
6. Remky A, Arend O, Jung F, Kiesewetter H, Reim M, Wolf S (1996) Haemorheology in patients with branch retinal vein occlusion with and without risk factors. Graefes Arch Clin Exp Ophthalmol 234(Suppl 1):S8–S12
7. Hansen LL, Wiek J, Wiederholt M (1989) A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 73:895–899
8. Kreutzer TC, Wolf A, Dirisamer M, Strauss RW, Foerster P, Feltgen N et al (2015) Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial. Ophthalmologica 233(1):8–17
9. Plunkett O, Lip PL, Lip GYH (2014) Atrial fibrillation and retinal vein or artery occlusion: looking beyond the eye. Br J Ophthalmol 98(9):1141–1143
10. Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W (2010) Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 103:271–276
11. BVOS (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 98:271–282
12. Lang GE (1993) Ergebnisse der Laserkoagulation beim retinalen Zentralvenenverschluss. Klin Monbl Augenheilkd 203(4):247–251
13. Pielen A, Mirshahi A, Feltgen N, Lorenz K, Korb C, Junker B et al (2015) Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 93(1):e29–e37
14. Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-Schmidt KU, Jaissle GB (2013) Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol 97(2):215–219
15. Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL et al (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina 34(9):1728–1735
16. Lang GE, Lang SJ (2010) Diagnose und Behandlung des retinalen Venenverschlusses. Klin Monbl Augenheilkd 227(10):R141–R154. (quiz R155)
17. Spaide RF (2013) Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion. Retina 33(1):56–62
18. Rehak M, Tilgner E, Franke A, Rauscher FG, Brosteanu O, Wiedemann P (2014) Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol 252(5):745–752
19. Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS ONE 8(10):e78538
20. German Ophthalmological Society; Retinological Society; Professional Association of German Ophthalmologists. Collaborators (13), Hoerauf H, Feltgen N, Bartz-Schmidt KU, Bertram B, Bornfeld N, Hansen LL, Heimann H, Helbig H, Kampik A, Kirchhof B, Lemmen KD, Pauleikhoff D, Roider J (2010) [Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists on Therapy for Macular Oedema in Cases of Retinal Vein Occlusion]. [Article in German]. Klin Monbl Augenheilkd 227(7):542–556. doi:10.1055/s-0029-1245534 (Epub 2010 Jul 19)
21. Huang P, Niu W, Ni Z, Wang R, Sun X (2013) A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PLoS ONE 8(12):e82454
22. Mitry D, Bunce C, Charteris D (2013) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 1:CD009510
23. Braithwaite T, Nanji AA, Lindsley K, Greenberg PB (2014) Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 5:CD007325
24. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049
25. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602
26. Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L et al (2014) Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 121(12):2432–2442
27. Epstein DLJ, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119(6):1184–1189
28. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS et al (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121(1):209–219
29. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429–437.e7
30. Korobelnik J-F, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept injection for macularedema resulting from central retinal veino cclusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208
31. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R et al (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122(3):538–544
32. Wang K, Wang Y, Gao L, Li X, Li M, Guo J (2008) Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 31(8):1541–1546
33. McAllister IL, Vijayasekaran S, Chen SD, Yu D-Y (2009) Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 147(5):838–846, 846.e1–2
34. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6):1134–1146.e3.
35. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127(9):1101–1114
36. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127(9):1115–1128
37. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–2460